How are energy investors positioned?
PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced that its Chief Financial Officer, Ken Myszkowski, is set to retire on May 13, 2025, marking the end of his 16-year tenure with the company. Daniel Apel will step into the CFO role, bringing with him substantial financial experience from his previous positions at Walgreens Boots Alliance and Bayer. According to InvestingPro data, Arrowhead, currently valued at $1.63 billion, maintains a strong liquidity position with a current ratio of 6.09, indicating robust short-term financial health despite recent market challenges.
Christopher Anzalone, Ph.D., President and CEO of Arrowhead, expressed gratitude for Myszkowski’s contributions, particularly highlighting the financial stability and robust support structure he established, which are vital as the company prepares for the potential launch of its new drug, plozasiran. InvestingPro analysis reveals that while the company is currently not profitable, analysts project significant sales growth, with revenue expected to increase by 38% in the current fiscal year. Get deeper insights into Arrowhead’s financial health and growth prospects with InvestingPro’s comprehensive research report, available along with 8 additional key ProTips.
Apel’s background includes serving as the Global Head of Financial Planning and Analysis at Walgreens from 2019 to 2024 and holding various significant roles during his nearly 20-year career at Bayer, including CFO positions in the United States and Canada. His experience is complemented by board memberships at the Biotechnology Innovation Organization and the Organization for International Investment, as well as a trusteeship at the Health Institute of New Jersey.
Arrowhead Pharmaceuticals focuses on developing RNAi-based therapeutics to silence genes responsible for intractable diseases. The company’s RNA interference mechanism is designed to induce rapid, deep, and durable knockdown of target genes. With its next earnings report scheduled for May 8, 2025, investors can access detailed financial analysis and Fair Value estimates through InvestingPro’s exclusive research tools and real-time metrics.
The forward-looking statements in this news release reflect Arrowhead’s current expectations and are subject to various risks and uncertainties, including regulatory review outcomes, clinical trial results, and financial performance projections. The company has cautioned that actual results may differ significantly due to these factors.
This article is based on a press release statement from Arrowhead Pharmaceuticals, Inc.
In other recent news, Arrowhead Pharmaceuticals has reported promising results from its Phase 1/2 study of ARO-C3, aimed at treating IgA nephropathy, a kidney disease. The study demonstrated significant reductions in key markers, including a sustained 87% reduction in complement component 3 (C3) and a 41% reduction in proteinuria by week 24. These findings were also noted by Goldman Sachs, which maintained a Neutral rating with a $26 price target, emphasizing the need for longer-term data. Meanwhile, H.C. Wainwright reaffirmed a Buy rating and an $80 price target, citing the potential of ARO-C3 to become a leading treatment for complement-mediated diseases.
Arrowhead Pharmaceuticals has also advanced its RNAi-based investigational therapeutics, ARO-INHBE and ARO-ALK7, into clinical trials for obesity and metabolic disease treatment. Preclinical data showed significant reductions in body fat while preserving lean muscle mass. The company is pioneering clinical studies on these targets, with initial results expected by the end of 2025. Additionally, Arrowhead recently held its 2025 Annual Meeting of Stockholders, where all proposed items, including board elections and executive compensation, were approved. The selection of KPMG LLP as the independent auditors for the fiscal year was also ratified.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.